Institute of Hematology & Blood Diseases Hospital
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-16 | NCT05456698 | |
| Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-03-02 | NCT07169500 | |
| Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-12-17 | NCT06387121 | |
| SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T lymphoblastic leukemia/lymphoma, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-12-15 | NCT07153068 | |
| Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | Primary Light-Chain Amyloidosis | Recruiting | Phase 2 | 2025-11-26 | NCT07039578 | |
| CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2025-11-25 | NCT07249073 | |
| Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 3 | 2025-09-18 | NCT07181239 | |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome | Recruiting | Phase 1 | 2025-09-11 | NCT07169487 | |
| uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T lymphoblastic leukemia/lymphoma, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-09-03 | NCT07109518 | |
| Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness | Platelet Transfusion Refractoriness | Recruiting | Phase 1 / Phase 2 | 2025-08-15 | NCT06792019 | |
| A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2025-08-12 | NCT05667506 | |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM | Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, neoplasm, plasma cell leukemia, plasma cell neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT07109323 | |
| Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection | B-cell Tumors | Recruiting | Not stated | 2025-08-07 | NCT06461351 | |
| CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm, viral infectious disease | Recruiting | Phase 1 | 2025-08-06 | NCT07106749 | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2025-05-30 | NCT05356169 | |
| Efficacy and Safety of Chidamide in CBF Leukemia | acute myeloid leukemia | Active, not recruiting | Phase 1 / Phase 2 | 2025-05-30 | NCT03031262 | |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | acute myeloid leukemia | Enrolling by invitation | Phase 1 / Phase 2 | 2025-05-30 | NCT03031249 | |
| Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML | acute myeloid leukemia | Active, not recruiting | Phase 3 | 2025-05-30 | NCT03021330 | |
| Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, blood platelet disease, connective tissue disorder, hematologic disorder, thrombocytopenia | Recruiting | Phase 2 | 2025-05-06 | NCT05998759 | |
| Β-Thalassemia Treatment with KL003 Cell Injection | Transfusion-dependent Beta-Thalassemia | Recruiting | Phase 1 / Phase 2 | 2025-03-10 | NCT06280378 | |
| Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-02-18 | NCT06791824 | |
| Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Not stated | 2024-09-19 | NCT06450067 |